Boston Scientific is ahead of earnings
BSX develops, manufactures and markets medical devices. The company operates primarily in the MedSurg (endoscopy, urology and neuromodulation) and Cardiovascular (cardiovascular interventions) business areas. In an effort to grow, BSX recently completed its third corporate acquisition in over a year, and there are likely more to come.
The company’s fiscal 2024 third quarter earnings report showed strong sales growth and adjusted earnings per share of $0.63 (up 27 percent). BSX’s consolidated revenue rose 19.4 percent from a year ago. Also, with $822 million in cash on hand and 15% annual revenue growth guidance, the company is poised for more growth (the next earnings announcement is scheduled for Feb. 5).
No wonder. BSX Shares are up nearly 60% a year — and could rise even more. MAPsignals data shows how Big Money investors are betting on the stock’s future picture.
Sizes of institutions show a lot. Recently, investor interest in BSX has been strong, which we believe is institutionally supported.
Each green bar shows unusually large volumes in BSX stocks. They reflect our proprietary flow signal, pushing the stock higher:
There are a lot of health care names piling up these days. But there is a powerful underlying story with Boston Scientific.
Institutional backing and sound fundamentals make this company worth checking out. As you can see, BSX had strong sales and revenue growth:
Source: FactSet
Also, EPS is estimated to rise by +13.8% this year.
Now it makes sense why the stock is soaring to new highs. BSX has a strong track record of financial performance.
Marrying great fundamentals with our proprietary software has yielded some big winning stocks over the long term.
Boston Scientific is the highest rated stock on MAPsignals. That means the stock has unusual buying pressure and bullish fundamentals. Every week we have a ranking process that features such stocks.
It has reported a top 20 appearance several times over the past year, including recently. The blue bars below show that BSX is the top pick… increasing over time.
Tracking unusual amounts shows the power of cash flow.
This is a characteristic of most foreign stocks…the best of the best. Big Money demand drives stocks higher.
The BSX lineup is by no means new. Big money’s buying into stocks is showing signs of giving notice. Given its historical gains in share price and strong fundamentals, this stock deserves a place in a diversified portfolio.